Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62.7M
-
Number of holders
-
236
-
Total 13F shares, excl. options
-
49.7M
-
Shares change
-
+671K
-
Total reported value, excl. options
-
$4.76B
-
Value change
-
+$6.32M
-
Put/Call ratio
-
0.72
-
Number of buys
-
111
-
Number of sells
-
-144
-
Price
-
$95.79
Significant Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q4 2018
335 filings reported holding SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") as of Q4 2018.
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) has 236 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.7M shares
of 62.7M outstanding shares and own 79.33% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (8.02M shares), FMR LLC (7.03M shares), Vanguard Group Inc (4.02M shares), BlackRock Inc. (2.51M shares), WELLINGTON MANAGEMENT GROUP LLP (1.92M shares), Bank of New York Mellon Corp (1.83M shares), OppenheimerFunds, Inc. (1.44M shares), BB BIOTECH AG (1.38M shares), STATE STREET CORP (1.06M shares), and FRANKLIN RESOURCES INC (1.04M shares).
This table shows the top 236 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.